Here are the 10-K annual reports from OnKure Therapeutics, Inc. (OKUR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow OKUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKUR filings page.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision small-molecule drugs targeting mutated PI3Kα in cancer, led by its oral H1047R‑selective inhibitor OKI‑219. OKI‑219 is in a multi-arm Phase 1 PIKture‑01 trial in solid tumors, including PI3KαH1047R‑mutated breast cancer, with early data showing a favorable tolerability profile and no hyperglycemia, stomatitis or rash observed as of an October 28, 2024 cutoff.
The company highlights a sizable commercial opportunity in PI3Kα‑mutated HR+/HER2‑ and HER2+ breast cancer and is also advancing a pan‑mutant PI3Kα discovery program and work in vascular malformations. However, it has no approved products, has incurred significant net losses, has never generated product revenue, and management has concluded that substantial doubt exists about its ability to continue as a going concern without additional capital.